Search Results
Your search for ,NOW matches 6738 pages
Showing 6601 - 6650Obesity Linked to Poor Survival in Patients With Tongue Cancer
Cancer experts from Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College are collaborating to understand the link between obesity and cancer. Most recently, their research has yielded an interesting association: Obesity prior to diagnosis is associated with a fivefold increase...
Optimized Radiation Treatment Schedule for Glioblastoma May Extend Survival
An altered radiation treatment schedule for glioblastoma, the most common and lethal form of brain cancer, extended the survival period of mice with the disease, according to a new study published in Cell. Because the research involved mice, the study does not recommend a specific new schedule for...
Bladder Cancer Study Uncovers Potential Drug Targets and Molecular Similarities to Other Cancers
Investigators with The Cancer Genome Atlas Research Network have identified new potential therapeutic targets for urothelial carcinoma of the bladder, a common cancer that causes about 150,000 deaths worldwide each year. The researchers also found molecular similarities to some subtypes of breast,...
Enzalutamide Improves Survival in Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer
Enzalutamide (Xtandi) improved survival by 29% in men with chemotherapy-naive metastatic castration-resistant prostate cancer and reduced the risk of radiographic progression by 81%, according to complete results of the randomized, double-blind, placebo-controlled, multinational, phase III PREVAIL...
Melatonin May Potentially Slow Tumor Growth in Estrogen Receptor–Negative Breast Cancers
An early-stage study shows melatonin may have the potential to help slow the growth of certain breast cancer tumors, according to researchers from Henry Ford Hospital in Detroit and Foundation for Research Support of the State of São Paulo. The study, published online in the journal PLoS...
Pilot Study Shows Promise of Neoadjuvant Chemotherapy Without Routine Radiotherapy in Patients With Locally Advanced Rectal Cancer
Neoadjuvant chemoradiotherapy delays administration of optimal chemotherapy in stage II to III rectal cancer. In a pilot study reported in the Journal of Clinical Oncology, Schrag et al assessed outcomes with neoadjuvant FOLFOX (fluorouracil, leucovorin, oxaliplatin)/bevacizumab (Avastin) with...
Ramucirumab Combination Improves Overall Survival After First Progression in Patients With Metastatic Gastric Cancer
In the global phase III RAINBOW trial of patients with metastatic gastric cancer, the investigational monoclonal antibody ramucirumab significantly improved both progression-free and overall survival when given as second-line therapy, investigators reported at a press briefing in advance of the...
Rates of New Lung Cancer Cases Drop in U.S. Men and Women
Tobacco control efforts are having a major impact on Americans’ health, a new analysis of lung cancer data suggests. The rate of new lung cancer cases decreased among men and women in the United States from 2005 to 2009, according to a report in this week’s Morbidity and Mortality...
ASCO Issues Statement in Response to American Cancer Society Report
Today the American Cancer Society issued a report showing a 20% decline in cancer death rates between 1991 and 2010, and estimating that 1.3 million deaths have been averted as a result of the decline. ASCO issued the following statement: “This is tremendous progress and a direct result ...
Most Physicians Would Enroll in Hospice If They Were Terminally Ill With Cancer, Study Finds
In a research letter published in JAMA Internal Medicine, Chinn et al surveyed physicians’ attitudes towards hospice treatment if they were terminally ill with cancer and assessed how physician preferences might affect timing of hospice discussions with their terminally ill patients. They...
FDA Approves Revised Prescribing Information for Ponatinib, Authorizes Resumption of Drug Sales and Distribution
The U.S. Food and Drug Administration (FDA) has approved revised prescribing information and a Risk Evaluation and Mitigation Strategy (REMS) for ponatinib (Iclusig) that allows immediate resumption of its marketing and commercial distribution. The prescribing information includes a revised...
Oral Ibandronic Acid Is Not Noninferior to IV Zoledronic Acid in Preventing Skeletal-Related Events in Patients With Breast Cancer
In a phase III noninferiority trial (ZICE) reported in The Lancet Oncology, Barrett-Lee et al compared oral ibandronic acid vs intravenous zoledronic acid in treatment of bone metastases from breast cancer. The study showed that ibandronic acid was not noninferior to zoledronic acid in preventing...
U.S. Cancer Death Rates Continue Decline, Annual Report Shows
Maintaining a 2 decade–long trend, the cancer death rate in the United States continues to decline, according to the Annual Report to the Nation on the Status of Cancer, published online this week in Cancer. The report, which covers the years 2001 to 2010, shows drops in death rates for a...
CALGB 40603 Trial Supports Adding Carboplatin to Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer
The addition of carboplatin to a neoadjuvant regimen significantly increased the rate of pathologic complete response in patients with triple-negative breast cancer. The results from the CALGB/Alliance 40603 study were reported at the 2013 San Antonio Breast Cancer Symposium (Abstract S5-01)....
PIK3CA Mutations Predictive of Resistance to Neoadjuvant Therapy in HER2/HR-Positive Breast Cancers
Women with HER2-positive, hormone receptor-positive breast cancer with mutations in the PI3K/AKT pathway may respond poorly to neoadjuvant therapy, German researchers reported at the 2013 San Antonio Breast Cancer Symposium (Abstract S4-06). “We found that very few women with HER2-positive...
Ibrutinib/Rituximab Combination Leads to High Response Rate Among Patients With CLL
Nearly all of the patients with high-risk chronic lymphocytic leukemia (CLL) in a phase II clinical trial responded to treatment with the targeted therapy ibrutinib (Imbruvica) and the antibody rituximab (Rituxan), researchers reported at the 55th American Society of Hematology (ASH) Annual Meeting ...
Biologic Mechanism May be Linked to Racial Disparities in Prostate Cancer
In the United States, African American men are 1.6 times more likely to develop prostate cancer and more than 2.5 times as likely to die from the disease than non-Hispanic white men, according to the U.S. Department of Health & Human Services. A study by David P. Turner, PhD, Assistant...
Obinutuzumab/Chlorambucil Superior to Rituximab/Chlorambucil as First-Line Treatment for Older CLL Patients With Comorbidities
Obinutuzumab (Gazyva) plus chlorambucil (Leukeran) was superior to rituximab (Rituximab) plus chlorambucil as first-line therapy in older chronic lymphocytic leukemia (CLL) patients with comorbidities, with an acceptable safety profile, according to final results of the phase III CLL11 trial....
Graft Manipulation Improves HLA-Haploidentical Hematopoietic Stem Cell Transplant Outcomes
T-cell–depleted HLA-haploidentical hematopoietic stem cell transplantation can be made more efficacious and safer through the removal of alpha/beta-positive T cells and CD19-positive B cells from the graft, an approach pioneered by Italian investigators who reported results at the 55th...
PIK3CA Mutation Fails to Predict Outcome of Irinotecan-Based Therapy in Stage III Colon Cancer
In a study reported in Journal of the National Cancer Institute, Shuji Ogino, MD, PhD, of Dana-Farber Cancer Institute and Harvard Medical School, and colleagues from the Alliance for Clinical Trials in Oncology evaluated the association of PIK3CA mutations with outcome in patients with stage III...
Tasquinimod May Improve Survival in Men With Metastatic Prostate Cancer
An investigational prostate cancer treatment slows the disease’s progression and may increase survival, especially among men whose cancer has spread to the bones, according an analysis led by the Duke Cancer Institute. The study, published in the journal Clinical Cancer Research, adds...
Less-Invasive Endoscopic Therapy as Effective as Esophagectomy in Early Esophageal Cancer
Use of a minimally invasive endoscopic procedure to remove superficial, early-stage esophageal cancer is as effective as surgery that takes out and rebuilds the esophagus, according to a study by researchers at Mayo Clinic in Florida. The research, published in Clinical Gastroenterology and...
Novel Agents Produce Encouraging Trends in Gastric Cancer
Several novel agents targeting the HER2, C-MET, and VEGF receptors have achieved encouraging results in gastric cancer, which is the second leading cause of cancer death worldwide. Charles Fuchs, MD, of Dana-Farber Cancer Institute, Boston, reviewed these new approaches in a presentation at the...
FDA Approves Transducer Array Layout System for Use in Patients With Recurrent Glioblastoma Multiforme
Novocure announced today that it has received U.S. Food and Drug Administration (FDA) approval for its NovoTAL (Transducer Array Layout) System through a Premarket Approval supplement. The NovoTAL System allows certified physicians to use the individual magnetic resonance imaging (MRI) data of...
Contemporary Breast Radiation Therapy Associated With Lower Risk of Major Coronary Events
A recent study by Darby and colleagues showed a significant linear increase in risk for major coronary events according to mean cardiac dose of radiation (7.4% per Gy) in patients receiving radiation therapy for breast cancer between 1958 and 2001. In an analysis reported in a research letter...
Online Training Tool Can Improve Pathway Adherence and Reduce Costs
A new educational tool for oncologists may enhance compliance with quality care standards and improve the value of cancer care, ultimately resulting in big cost savings for health-care systems, according to Karen Fields, MD, and colleagues from H. Lee Moffitt Cancer Center and Research Institute,...
Complete Sequencing of All Known Breast Cancer Genes Explains Occurrence of the Cancer in Women With Normal BRCA Genes
Since 1994, many thousands of women with breast cancer from families severely affected with the disease have been tested for inherited mutations in BRCA1 and BRCA2, and the vast majority of those patients were told that their gene sequences were normal. With the development of modern genomics...
Bone Marrow Transplant Linked to Negative Sexual Side Effects in Both Men and Women
New research ties preparative procedures and complications associated with blood or bone marrow transplant with diminished sexual health in both men and women who have undergone the procedure. Study data, published today in Blood, confirm chronic graft-vs-host disease as a potential source of...
New Nanopharmaceutical May Be Able to Overcome Resistance to Antiangiogenic Treatment
The nanopharmaceutical CRLX101, a novel inhibitor of topoisomerase-1 and hypoxia-inducible factor (HIF)-1 alpha, may be capable of overcoming resistance of tumors to antiangiogenic agents, according to preclinical and early clinical studies that have evaluated CRLX101 in combination with...
Long-Term Obesity Is Linked With Poorer Pancreatic Cancer Survival
Although multiple studies have shown that high body mass index (BMI) is associated with an increased risk of developing pancreatic cancer, few studies have evaluated the impact of BMI on survival and none have used prospectively collected data on BMI. Now a large prospective study by Brian M....
NIH Awards $17 Million in Grants to Augment Genomics Research in Africa
The National Institutes of Health has awarded 10 new grants totaling up to $17 million over the next 4 years to support genomics research in Africa, as part of the Human Heredity and Health in Africa (H3Africa) program. This set of grants is the second disbursement of H3Africa awards and brings the ...
Standard and Reduced High-Dose Volume Radiation Therapy for Muscle-Invasive Bladder Cancer Have Comparable Tumor Control
Standard and reduced high-dose volume radiation therapy for muscle-invasive bladder cancer provide comparable tumor control and decreased late toxicity when compared to surgery, according to a study published in the October issue of the International Journal of Radiation Oncology...
Program Chairs Highlight Abstracts of Interest for the 2013 CTRC-AACR San Antonio Breast Cancer Symposium
The Program Chairs of the 2013 CTRC-AACR San Antonio Breast Cancer Symposium, which will be held December 10–14, 2013, have highlighted what they consider to be the most important abstracts to be presented at the Symposium. In a telebriefing in advance of the December meeting, C. Kent...
Treatment With Losartan May Improve Delivery of Chemotherapy Drugs in Tumors
Use of existing, well-established hypertension drugs could improve the outcome of cancer chemotherapy by opening up collapsed blood vessels in solid tumors. In a report published in Nature Communications, investigators from Massachusetts General Hospital (MGH) described how the angiotensin...
Men With Advanced Prostate Cancer Worry More About Burdening Family and Friends Than Dying, Survey Finds
Men with advanced prostate cancer are now living longer than ever, and it is estimated that one in six U.S. men will be diagnosed with prostate cancer in their lifetime. However, little research has been conducted to understand the psychosocial needs of these men and their caregivers after...
Telomere Length May Be a Prognostic Marker for Prostate Cancer
Cancer cells are known to have short telomeres, but just how short they are from cancer cell to cancer cell may be a determining factor in a prostate cancer patient's prognosis, according to a study led by scientists at Johns Hopkins. "Doctors are looking for new ways to accurately predict...
ASTRO: Fewer Weeks of Neoadjuvant Hormone Therapy Reduces Side Effects in Patients With Intermediate-Risk Prostate Cancer
A shorter course of androgen suppression therapy prior to radiation therapy, when compared to an extended course of androgen suppression therapy, yields comparable outcomes and fewer adverse effects for intermediate-risk prostate cancer patients, according to research presented today at the...
NCCN: Practical Considerations in Selecting Tyrosine Kinase Inhibitor Therapy for Chronic Myeloid Leukemia
Although imatinib (Gleevec) is the initial therapy for chronic myeloid leukemia (CML), several second-generation tyrosine kinase inhibitors are now approved for the treatment of this disease. Michael Millenson, MD, of Fox Chase Cancer Center in Philadelphia, reviewed practical considerations in...
Researchers Uncover Root Cause of Multiple Myeloma Relapse
Researchers have discovered why multiple myeloma frequently recurs after an initially effective treatment that can keep the disease at bay for up to several years. The study, published in Cancer Cell, was a collaboration between researchers at Princess Margaret Hospital in Toronto, Mayo Clinic in...
Statement by ASCO President Clifford A. Hudis, MD, FACP, in Support of the Rally for Medical Research Hill Day
“With the unprecedented scientific opportunities now promising significant progress against cancer and other life-threatening diseases, it is a tragedy that we are even considering cuts to our nation's investment in biomedical research. Yet, such cuts are already happening because of the...
PDK1 Gene Identified as New Target for Melanoma Treatment
According to new research at Sanford-Burnham Medical Research Institute a gene encoding the enzyme phosphoinositide-dependent kinase-1 (PDK1) plays an essential role in the development and progression of melanoma. The finding, published online in Oncogene, may offer insight toward a new approach to ...
Exploratory Analysis Suggests Response-Guided Neoadjuvant Therapy for Breast Cancer May Improve Survival
In an exploratory analysis of long-term survival data from the GeparTrio trial reported in Journal of Clinical Oncology, Gunter von Minckwitz, MD, of the German Breast Group in Neu-Isenburg, and colleagues found that response-guided neoadjuvant chemotherapy appears to improve disease-free survival...
Dana-Farber Mourns the Passing of Jane Carrie Weeks, MD, MSc, National Leader in Outcomes Research
Jane Carrie Weeks, MD, MSc, a prominent researcher at Dana-Farber Cancer Institute, internationally known for building the discipline of outcomes research in oncology and admired by colleagues as an outstanding mentor, died September 10 after a long illness. She was "one of the true intellectual...
Breast Cancer Treatment in 10 Years: George Sledge, MD, Offers His Predictions
In a keynote lecture during the 2013 Breast Cancer Symposium breast cancer expert and ASCO Past President George Sledge, MD, offered five predictions for the future of the medical management of breast cancer. Dr. Sledge is now Chief of Oncology at Stanford University School of Medicine, Palo Alto,...
Dr. Larry Norton, Honored at 2013 Breast Cancer Symposium, Calls for Return to the ‘Exploration of Concepts’
Larry Norton, MD, of Memorial Sloan-Kettering Cancer Center, is the recipient of the 2013 Gianni Bonadonna Breast Cancer Award, which he received at the 2013 Breast Cancer Symposium. The Symposium is sponsored by ASCO, the American Society of Breast Surgeons, the American Society of Radiation...
New Laser-Based Tool Could Dramatically Improve the Accuracy of Brain Tumor Surgery
A new laser-based technology may make brain tumor surgery much more accurate, allowing surgeons to tell cancer tissue from normal brain at the microscopic level while they are operating, and avoid leaving behind cells that could spawn a new tumor. In a new paper published in Science Translational...
MRI Around the Time of Surgery Does Not Reduce Recurrence Rates in Women With DCIS
A large retrospective study reported that adding magnetic resonance imaging (MRI) to mammography before or immediately after surgery was not associated with reduced local recurrence or contralateral breast cancer rates among women with ductal carcinoma in situ (DCIS) of the breast who were treated...
FDA Approves Mechlorethamine Gel for Cutaneous T-Cell Lymphoma
Ceptaris Therapeutics, Inc, announced today that the U.S. Food and Drug Administration (FDA) has granted marketing approval for the orphan drug mechlorethamine gel (Valchlor) for the topical treatment of stage IA and IB mycosis fungoides-type cutaneous T-cell lymphoma (CTCL) in patients who...
Smoking Cessation and Prevention App Free on iTunes
An app to prevent teens from smoking and encourage them to quit if they have started is now available at no cost on the Apple iTunes Store. “Our app combines education and entertainment with comics and interactive games,” said Designer Alexander Prokhorov, MD, PhD, a Professor in the...
Preclinical Tests May Lead to New Approach to Treat CNS Lymphoma
A drug recently approved for use in multiple myeloma is now being tested for its ability to fight central nervous system (CNS) lymphoma, a deadly cancer of the immune system that can affect the brain, spinal cord and fluid, and eyes. The clinical trial, now open at the three campuses of Mayo Clinic ...
